drugset / Trial / NCT04943718
Personalized Vaccine for Patients With Recurrent Malignant Glioma
Phase 1
Unknown
10 enrolled
Xuanwu Hospital, Beijing
Beijing Neoantigen Biotechnology Company · collab
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.
Timeline
- Start
- 2021-07-15
- Primary completion
- 2023-06-13
- Completion
- 2024-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | personalized vaccine | Vaccine | — | Subcutaneous |